Topal E, Kovan B, Iribas A, Kuyumcu S, Basaran M, Malcok Demirtas A
Eur J Nucl Med Mol Imaging. 2025; .
PMID: 40063298
DOI: 10.1007/s00259-025-07125-1.
Ono T, Uto M, Mineharu Y, Arakawa Y, Nakamura M, Nishio T
Radiat Oncol. 2025; 20(1):32.
PMID: 40059195
PMC: 11890525.
DOI: 10.1186/s13014-025-02612-z.
Hamada N, Kawano K, Hirota S, Yusoff F, Nomura T, Saito Y
Sci Rep. 2025; 15(1):7712.
PMID: 40044924
PMC: 11883035.
DOI: 10.1038/s41598-025-92710-5.
Menon S, Sahu S, Mitra A, Chakraborty A, Malhotra G, Kamaldeep
Sci Rep. 2025; 15(1):6476.
PMID: 39987209
PMC: 11846852.
DOI: 10.1038/s41598-024-84096-7.
Costin I, Marcu L
Heliyon. 2025; 11(3):e42176.
PMID: 39959482
PMC: 11830291.
DOI: 10.1016/j.heliyon.2025.e42176.
Sex-Based Bias in Artificial Intelligence-Based Segmentation Models in Clinical Oncology.
Doo F, Naranjo W, Kapouranis T, Thor M, Chao M, Yang X
Clin Oncol (R Coll Radiol). 2025; 39:103758.
PMID: 39874747
PMC: 11850178.
DOI: 10.1016/j.clon.2025.103758.
Papillary Tumor of the Pineal Region Treated With Surgery and Postoperative Radiotherapy: A Case Report.
Royal-Preyra B, Boucher M
Cureus. 2025; 17(1):e77989.
PMID: 39867506
PMC: 11763826.
DOI: 10.7759/cureus.77989.
Dosimetric and Radiobiological Impact of Patient Setup Errors in Intensity-modulated Radiotherapy for Esophageal Cancer.
Cai J, Peng X, Lu J
Technol Cancer Res Treat. 2025; 24():15330338241311136.
PMID: 39840692
PMC: 11755542.
DOI: 10.1177/15330338241311136.
Initial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S
Front Oncol. 2025; 14():1483953.
PMID: 39839782
PMC: 11745944.
DOI: 10.3389/fonc.2024.1483953.
Minimizing Long-Term Toxicities for Patients with Primary Mediastinal B-Cell Lymphoma Undergoing Modern Radiotherapy: Results from a Monocentric Biophysical Risk Evaluation.
Baehr A, Schafer S, Jackel M, Becker S, Ghandili S, Grohmann M
Cancers (Basel). 2025; 16(24.
PMID: 39766164
PMC: 11674985.
DOI: 10.3390/cancers16244265.
Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.
Bagheri R, Ranjbar H
Asia Ocean J Nucl Med Biol. 2025; 13(1):94-101.
PMID: 39744057
PMC: 11682468.
DOI: 10.22038/aojnmb.2024.79679.1560.
Nanotechnology for the Diagnosis and Treatment of Liver Cancer.
Cai Y, Wang W, Jiao Q, Hu T, Ren Y, Su X
Int J Nanomedicine. 2024; 19:13805-13821.
PMID: 39735328
PMC: 11681781.
DOI: 10.2147/IJN.S490661.
Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303).
Shinkai M, Imano M, Yokokawa M, Matsuyama J, Kimura Y, Shimokawa T
Med Oncol. 2024; 42(1):31.
PMID: 39699794
DOI: 10.1007/s12032-024-02583-3.
Replacing 2 Gy Per Fraction Equivalent Dose with Fractionation-Specific Biological Equivalent Dose for Normal Tissues.
Luo W, Clair W
Int J Mol Sci. 2024; 25(23).
PMID: 39684602
PMC: 11641765.
DOI: 10.3390/ijms252312891.
Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.
Tejada Ortigosa E, Ollinger Casin I, Gaztelu Blanco I, Muniz Romero G, de Haro Piedra R
Clin Transl Oncol. 2024; .
PMID: 39680268
DOI: 10.1007/s12094-024-03786-w.
DNA double-strand break repair capacity and normal tissue toxicity induced by radiotherapy.
Nishibuchi I, Tashiro S
J Radiat Res. 2024; 65(Supplement_1):i52-i56.
PMID: 39679883
PMC: 11647926.
DOI: 10.1093/jrr/rrae081.
Preclinical Comparison of [In]In- and [Ac]Ac-DOTA-Trastuzumab IgG, F(ab') and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer.
Kondo M, Cai Z, Chan C, Brown M, Reilly R
Mol Pharm. 2024; 22(1):474-487.
PMID: 39666273
PMC: 11708818.
DOI: 10.1021/acs.molpharmaceut.4c01071.
On the impact of improved dose calculation accuracy in clinical treatment planning for superficial high-dose-rate brachytherapy of extensive scalp lesions.
Rossi G, Peppa V, Gainey M, Kollefrath M, Sprave T, Papagiannis P
Phys Imaging Radiat Oncol. 2024; 32:100673.
PMID: 39633875
PMC: 11616074.
DOI: 10.1016/j.phro.2024.100673.
Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation.
Murr M, Wegener D, Boke S, Gani C, Monnich D, Niyazi M
Phys Imaging Radiat Oncol. 2024; 32:100662.
PMID: 39554802
PMC: 11564916.
DOI: 10.1016/j.phro.2024.100662.
Automatic Treatment Planning for Radiation Therapy: A Cross-Modality and Protocol Study.
Szalkowski G, Xu X, Das S, Yap P, Lian J
Adv Radiat Oncol. 2024; 9(12):101649.
PMID: 39553397
PMC: 11566342.
DOI: 10.1016/j.adro.2024.101649.